Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 314

1.

Brainstem pathology in amyotrophic lateral sclerosis and primary lateral sclerosis: A longitudinal neuroimaging study.

Bede P, Chipika RH, Finegan E, Li Hi Shing S, Doherty MA, Hengeveld JC, Vajda A, Hutchinson S, Donaghy C, McLaughlin RL, Hardiman O.

Neuroimage Clin. 2019 Oct 24;24:102054. doi: 10.1016/j.nicl.2019.102054. [Epub ahead of print]

2.

Group interventions for amyotrophic lateral sclerosis caregivers in Ireland: a randomised controlled trial protocol.

Burke T, Wilson O'Raghallaigh J, Maguire S, Galvin M, Heverin M, Hardiman O, Pender N.

BMJ Open. 2019 Sep 20;9(9):e030684. doi: 10.1136/bmjopen-2019-030684.

3.

Generation of six induced pluripotent stem cell (iPSC) lines from two patients with amyotrophic lateral sclerosis (NUIGi043-A, NUIGi043-B, NUIGi043-C, NUIGi044-A, NUIGi044-B, NUIGi044-C).

Yang M, Liu M, Vajda A, O'Brien T, Henshall D, Hardiman O, Shen S.

Stem Cell Res. 2019 Oct;40:101558. doi: 10.1016/j.scr.2019.101558. Epub 2019 Aug 29.

4.

Effect modification of the association between total cigarette smoking and ALS risk by intensity, duration and time-since-quitting: Euro-MOTOR.

Peters S, Visser AE, D'Ovidio F, Vlaanderen J, Portengen L, Beghi E, Chio A, Logroscino G, Hardiman O, Pupillo E, Veldink JH, Vermeulen R, van den Berg LH; Euro-MOTOR consortium.

J Neurol Neurosurg Psychiatry. 2019 Aug 21. pii: jnnp-2019-320986. doi: 10.1136/jnnp-2019-320986. [Epub ahead of print]

PMID:
31434759
5.

Post-polio Syndrome: More Than Just a Lower Motor Neuron Disease.

Li Hi Shing S, Chipika RH, Finegan E, Murray D, Hardiman O, Bede P.

Front Neurol. 2019 Jul 16;10:773. doi: 10.3389/fneur.2019.00773. eCollection 2019. Review.

6.

Patterned functional network disruption in amyotrophic lateral sclerosis.

Dukic S, McMackin R, Buxo T, Fasano A, Chipika R, Pinto-Grau M, Costello E, Schuster C, Hammond M, Heverin M, Coffey A, Broderick M, Iyer PM, Mohr K, Gavin B, Pender N, Bede P, Muthuraman M, Lalor EC, Hardiman O, Nasseroleslami B.

Hum Brain Mapp. 2019 Nov 1;40(16):4827-4842. doi: 10.1002/hbm.24740. Epub 2019 Jul 26.

7.

Lifetime Risk and Heritability of Amyotrophic Lateral Sclerosis.

Ryan M, Heverin M, McLaughlin RL, Hardiman O.

JAMA Neurol. 2019 Jul 22. doi: 10.1001/jamaneurol.2019.2044. [Epub ahead of print]

PMID:
31329211
8.

The clinical and radiological profile of primary lateral sclerosis: a population-based study.

Finegan E, Chipika RH, Li Hi Shing S, Doherty MA, Hengeveld JC, Vajda A, Donaghy C, McLaughlin RL, Pender N, Hardiman O, Bede P.

J Neurol. 2019 Nov;266(11):2718-2733. doi: 10.1007/s00415-019-09473-z. Epub 2019 Jul 19.

PMID:
31325016
9.

Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial.

Al-Chalabi A, Shaw P, Leigh PN, van den Berg L, Hardiman O, Ludolph A, Aho VV, Sarapohja T, Kuoppamäki M.

J Neurol Neurosurg Psychiatry. 2019 Oct;90(10):1165-1170. doi: 10.1136/jnnp-2018-320288. Epub 2019 Jul 17.

10.

Longitudinal analysis of sniff nasal inspiratory pressure assessed using occluded and un-occluded measurement techniques in amyotrophic lateral sclerosis and primary lateral sclerosis.

Murray D, Rooney J, Campion A, Fenton L, Hammond M, Heverin M, Meldrum D, Moloney H, Tattersall R, Hardiman O.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(7-8):481-489. doi: 10.1080/21678421.2019.1639194. Epub 2019 Jul 17.

PMID:
31313597
11.

A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis.

Shefner JM, Cudkowicz ME, Hardiman O, Cockcroft BM, Lee JH, Malik FI, Meng L, Rudnicki SA, Wolff AA, Andrews JA; VITALITY-ALS Study Group.

Amyotroph Lateral Scler Frontotemporal Degener. 2019;0(0):1-11. doi: 10.1080/21678421.2019.1612922. Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2019 Jul 14;:1.

PMID:
31081694
12.

Exome array analysis of rare and low frequency variants in amyotrophic lateral sclerosis.

Dekker AM, Diekstra FP, Pulit SL, Tazelaar GHP, van der Spek RA, van Rheenen W, van Eijk KR, Calvo A, Brunetti M, Damme PV, Robberecht W, Hardiman O, McLaughlin R, Chiò A, Sendtner M, Ludolph AC, Weishaupt JH, Pardina JSM, van den Berg LH, Veldink JH.

Sci Rep. 2019 Apr 11;9(1):5931. doi: 10.1038/s41598-019-42091-3.

13.

Two heads are better than one: benefits of joint models for ALS trials.

van Eijk RPA, Rooney J, Hardiman O, van den Berg LH.

J Neurol Neurosurg Psychiatry. 2019 Sep;90(9):1071-1072. doi: 10.1136/jnnp-2019-320553. Epub 2019 Apr 11. No abstract available.

PMID:
30975822
14.

Pathological Crying and Laughing in Motor Neuron Disease: Pathobiology, Screening, Intervention.

Finegan E, Chipika RH, Li Hi Shing S, Hardiman O, Bede P.

Front Neurol. 2019 Mar 21;10:260. doi: 10.3389/fneur.2019.00260. eCollection 2019. Review.

15.

Tracking a Fast-Moving Disease: Longitudinal Markers, Monitoring, and Clinical Trial Endpoints in ALS.

Chipika RH, Finegan E, Li Hi Shing S, Hardiman O, Bede P.

Front Neurol. 2019 Mar 19;10:229. doi: 10.3389/fneur.2019.00229. eCollection 2019. Review.

16.

Multicentre, population-based, case-control study of particulates, combustion products and amyotrophic lateral sclerosis risk.

Visser AE, D'Ovidio F, Peters S, Vermeulen RC, Beghi E, Chiò A, Veldink JH, Logroscino G, Hardiman O, van den Berg LH; Euro-MOTOR consortium.

J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):854-860. doi: 10.1136/jnnp-2018-319779. Epub 2019 Mar 8.

PMID:
30850472
17.

Comparison of the clinical and genetic features of amyotrophic lateral sclerosis across Cuban, Uruguayan and Irish clinic-based populations.

Ryan M, Zaldívar Vaillant T, McLaughlin RL, Doherty MA, Rooney J, Heverin M, Gutierrez J, Lara-Fernández GE, Pita Rodríguez M, Hackembruch J, Perna A, Vazquez MC, Musio M, Ketzoian CN, Logroscino G, Hardiman O.

J Neurol Neurosurg Psychiatry. 2019 Jun;90(6):659-665. doi: 10.1136/jnnp-2018-319838. Epub 2019 Mar 7.

PMID:
30846540
18.

Mutations in the Glycosyltransferase Domain of GLT8D1 Are Associated with Familial Amyotrophic Lateral Sclerosis.

Cooper-Knock J, Moll T, Ramesh T, Castelli L, Beer A, Robins H, Fox I, Niedermoser I, Van Damme P, Moisse M, Robberecht W, Hardiman O, Panades MP, Assialioui A, Mora JS, Basak AN, Morrison KE, Shaw CE, Al-Chalabi A, Landers JE, Wyles M, Heath PR, Higginbottom A, Walsh T, Kazoka M, McDermott CJ, Hautbergue GM, Kirby J, Shaw PJ.

Cell Rep. 2019 Feb 26;26(9):2298-2306.e5. doi: 10.1016/j.celrep.2019.02.006.

19.

Measuring network disruption in neurodegenerative diseases: New approaches using signal analysis.

McMackin R, Muthuraman M, Groppa S, Babiloni C, Taylor JP, Kiernan MC, Nasseroleslami B, Hardiman O.

J Neurol Neurosurg Psychiatry. 2019 Sep;90(9):1011-1020. doi: 10.1136/jnnp-2018-319581. Epub 2019 Feb 13. Review.

20.

Neurophysiological markers of network dysfunction in neurodegenerative diseases.

McMackin R, Bede P, Pender N, Hardiman O, Nasseroleslami B.

Neuroimage Clin. 2019;22:101706. doi: 10.1016/j.nicl.2019.101706. Epub 2019 Feb 2. Review.

21.

Dysfunction of attention switching networks in amyotrophic lateral sclerosis.

McMackin R, Dukic S, Broderick M, Iyer PM, Pinto-Grau M, Mohr K, Chipika R, Coffey A, Buxo T, Schuster C, Gavin B, Heverin M, Bede P, Pender N, Lalor EC, Muthuraman M, Hardiman O, Nasseroleslami B.

Neuroimage Clin. 2019;22:101707. doi: 10.1016/j.nicl.2019.101707. Epub 2019 Feb 2.

22.

Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach.

Kueffner R, Zach N, Bronfeld M, Norel R, Atassi N, Balagurusamy V, Di Camillo B, Chio A, Cudkowicz M, Dillenberger D, Garcia-Garcia J, Hardiman O, Hoff B, Knight J, Leitner ML, Li G, Mangravite L, Norman T, Wang L; ALS Stratification Consortium, Xiao J, Fang WC, Peng J, Yang C, Chang HJ, Stolovitzky G.

Sci Rep. 2019 Jan 24;9(1):690. doi: 10.1038/s41598-018-36873-4.

23.

Building a supportive framework for brain research in Ireland: Inaugural position paper of the Irish Brain Council.

Rogers M, Boland B, Clarke S, Craven A, Fassbender C, Gill M, Hardiman O, Henshall DC, Lynch T, Mitchell K, Pender N, Rogan C, Roche RAP.

Eur J Neurosci. 2019 Jun;49(11):1362-1370. doi: 10.1111/ejn.14351. Epub 2019 Feb 19. No abstract available.

PMID:
30673123
24.

Primary lateral sclerosis: a distinct entity or part of the ALS spectrum?

Finegan E, Chipika RH, Shing SLH, Hardiman O, Bede P.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 May;20(3-4):133-145. doi: 10.1080/21678421.2018.1550518. Epub 2019 Jan 18.

PMID:
30654671
25.

Associations of Electric Shock and Extremely Low-Frequency Magnetic Field Exposure With the Risk of Amyotrophic Lateral Sclerosis.

Peters S, Visser AE, D'Ovidio F, Beghi E, Chiò A, Logroscino G, Hardiman O, Kromhout H, Huss A, Veldink J, Vermeulen R, van den Berg LH; Euro-MOTOR Consortium.

Am J Epidemiol. 2019 Apr 1;188(4):796-805. doi: 10.1093/aje/kwy287.

PMID:
30649156
26.

Global burden of motor neuron diseases: mind the gaps.

Hardiman O.

Lancet Neurol. 2018 Dec;17(12):1030-1031. doi: 10.1016/S1474-4422(18)30398-3. Epub 2018 Nov 5. No abstract available.

27.

Association of NIPA1 repeat expansions with amyotrophic lateral sclerosis in a large international cohort.

Tazelaar GHP, Dekker AM, van Vugt JJFA, van der Spek RA, Westeneng HJ, Kool LJBG, Kenna KP, van Rheenen W, Pulit SL, McLaughlin RL, Sproviero W, Iacoangeli A, Hübers A, Brenner D, Morrison KE, Shaw PJ, Shaw CE, Panadés MP, Mora Pardina JS, Glass JD, Hardiman O, Al-Chalabi A, van Damme P, Robberecht W, Landers JE, Ludolph AC, Weishaupt JH, van den Berg LH, Veldink JH, van Es MA; Project MinE ALS Sequencing Consortium.

Neurobiol Aging. 2019 Feb;74:234.e9-234.e15. doi: 10.1016/j.neurobiolaging.2018.09.012. Epub 2018 Sep 22.

28.

ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS.

Crockford C, Newton J, Lonergan K, Chiwera T, Booth T, Chandran S, Colville S, Heverin M, Mays I, Pal S, Pender N, Pinto-Grau M, Radakovic R, Shaw CE, Stephenson L, Swingler R, Vajda A, Al-Chalabi A, Hardiman O, Abrahams S.

Neurology. 2018 Oct 9;91(15):e1370-e1380. doi: 10.1212/WNL.0000000000006317. Epub 2018 Sep 12.

29.

Association between alcohol exposure and the risk of amyotrophic lateral sclerosis in the Euro-MOTOR study.

D'Ovidio F, Rooney JPK, Visser AE, Manera U, Beghi E, Logroscino G, Vermeulen RCH, Veldink JH, van den Berg LH, Hardiman O, Chiò A; Euro-MOTOR consortium.

J Neurol Neurosurg Psychiatry. 2019 Jan;90(1):11-19. doi: 10.1136/jnnp-2018-318559. Epub 2018 Aug 3.

PMID:
30076269
30.

The multistep hypothesis of ALS revisited: The role of genetic mutations.

Chiò A, Mazzini L, D'Alfonso S, Corrado L, Canosa A, Moglia C, Manera U, Bersano E, Brunetti M, Barberis M, Veldink JH, van den Berg LH, Pearce N, Sproviero W, McLaughlin R, Vajda A, Hardiman O, Rooney J, Mora G, Calvo A, Al-Chalabi A.

Neurology. 2018 Aug 14;91(7):e635-e642. doi: 10.1212/WNL.0000000000005996. Epub 2018 Jul 25.

31.

ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function.

de Majo M, Topp SD, Smith BN, Nishimura AL, Chen HJ, Gkazi AS, Miller J, Wong CH, Vance C, Baas F, Ten Asbroek ALMA, Kenna KP, Ticozzi N, Redondo AG, Esteban-Pérez J, Tiloca C, Verde F, Duga S, Morrison KE, Shaw PJ, Kirby J, Turner MR, Talbot K, Hardiman O, Glass JD, de Belleroche J, Gellera C, Ratti A, Al-Chalabi A, Brown RH, Silani V, Landers JE, Shaw CE.

Neurobiol Aging. 2018 Nov;71:266.e1-266.e10. doi: 10.1016/j.neurobiolaging.2018.06.015. Epub 2018 Jun 25.

32.

The life expectancy of Stephen Hawking, according to the ENCALS model.

Westeneng HJ, Al-Chalabi A, Hardiman O, Debray TP, van den Berg LH.

Lancet Neurol. 2018 Aug;17(8):662-663. doi: 10.1016/S1474-4422(18)30241-2. Epub 2018 Jul 17. No abstract available.

PMID:
30033055
33.

Determining the incidence of familiality in ALS: A study of temporal trends in Ireland from 1994 to 2016.

Ryan M, Heverin M, Doherty MA, Davis N, Corr EM, Vajda A, Pender N, McLaughlin R, Hardiman O.

Neurol Genet. 2018 May 18;4(3):e239. doi: 10.1212/NXG.0000000000000239. eCollection 2018 Jun.

34.

The Study of Language in the Amyotrophic Lateral Sclerosis - Frontotemporal Spectrum Disorder: a Systematic Review of Findings and New Perspectives.

Pinto-Grau M, Hardiman O, Pender N.

Neuropsychol Rev. 2018 Jun;28(2):251-268. doi: 10.1007/s11065-018-9375-7. Epub 2018 Apr 28.

PMID:
29705950
35.

Multicentre, cross-cultural, population-based, case-control study of physical activity as risk factor for amyotrophic lateral sclerosis.

Visser AE, Rooney JPK, D'Ovidio F, Westeneng HJ, Vermeulen RCH, Beghi E, Chiò A, Logroscino G, Hardiman O, Veldink JH, van den Berg LH; Euro-MOTOR consortium.

J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):797-803. doi: 10.1136/jnnp-2017-317724. Epub 2018 Apr 23.

PMID:
29685899
36.

Understanding the use of NIV in ALS: results of an international ALS specialist survey.

Heiman-Patterson TD, Cudkowicz ME, De Carvalho M, Genge A, Hardiman O, Jackson CE, Lechtzin N, Mitsumoto H, Silani V, Andrews JA, Chen D, Kulke S, Rudnicki SA, van den Berg LH.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):331-341. doi: 10.1080/21678421.2018.1457058. Epub 2018 Apr 16.

PMID:
29661084
37.

Referral bias in ALS epidemiological studies.

Logroscino G, Marin B, Piccininni M, Arcuti S, Chiò A, Hardiman O, Rooney J, Zoccolella S, Couratier P, Preux PM, Beghi E; for EURALS.

PLoS One. 2018 Apr 16;13(4):e0195821. doi: 10.1371/journal.pone.0195821. eCollection 2018.

38.

Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model.

Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, Martin S, McDermott CJ, Thompson AG, Pinto S, Kobeleva X, Rosenbohm A, Stubendorff B, Sommer H, Middelkoop BM, Dekker AM, van Vugt JJFA, van Rheenen W, Vajda A, Heverin M, Kazoka M, Hollinger H, Gromicho M, Körner S, Ringer TM, Rödiger A, Gunkel A, Shaw CE, Bredenoord AL, van Es MA, Corcia P, Couratier P, Weber M, Grosskreutz J, Ludolph AC, Petri S, de Carvalho M, Van Damme P, Talbot K, Turner MR, Shaw PJ, Al-Chalabi A, Chiò A, Hardiman O, Moons KGM, Veldink JH, van den Berg LH.

Lancet Neurol. 2018 May;17(5):423-433. doi: 10.1016/S1474-4422(18)30089-9. Epub 2018 Mar 26.

39.

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.

Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, Dominov JA, Kenna BJ, Nalls MA, Keagle P, Rivera AM, van Rheenen W, Murphy NA, van Vugt JJFA, Geiger JT, Van der Spek RA, Pliner HA, Shankaracharya, Smith BN, Marangi G, Topp SD, Abramzon Y, Gkazi AS, Eicher JD, Kenna A; ITALSGEN Consortium, Mora G, Calvo A, Mazzini L, Riva N, Mandrioli J, Caponnetto C, Battistini S, Volanti P, La Bella V, Conforti FL, Borghero G, Messina S, Simone IL, Trojsi F, Salvi F, Logullo FO, D'Alfonso S, Corrado L, Capasso M, Ferrucci L; Genomic Translation for ALS Care (GTAC) Consortium, Moreno CAM, Kamalakaran S, Goldstein DB; ALS Sequencing Consortium, Gitler AD, Harris T, Myers RM; NYGC ALS Consortium, Phatnani H, Musunuri RL, Evani US, Abhyankar A, Zody MC; Answer ALS Foundation, Kaye J, Finkbeiner S, Wyman SK, LeNail A, Lima L, Fraenkel E, Svendsen CN, Thompson LM, Van Eyk JE, Berry JD, Miller TM, Kolb SJ, Cudkowicz M, Baxi E; Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium, Benatar M, Taylor JP, Rampersaud E, Wu G, Wuu J; SLAGEN Consortium, Lauria G, Verde F, Fogh I, Tiloca C, Comi GP, Sorarù G, Cereda C; French ALS Consortium, Corcia P, Laaksovirta H, Myllykangas L, Jansson L, Valori M, Ealing J, Hamdalla H, Rollinson S, Pickering-Brown S, Orrell RW, Sidle KC, Malaspina A, Hardy J, Singleton AB, Johnson JO, Arepalli S, Sapp PC, McKenna-Yasek D, Polak M, Asress S, Al-Sarraj S, King A, Troakes C, Vance C, de Belleroche J, Baas F, Ten Asbroek ALMA, Muñoz-Blanco JL, Hernandez DG, Ding J, Gibbs JR, Scholz SW, Floeter MK, Campbell RH, Landi F, Bowser R, Pulst SM, Ravits JM, MacGowan DJL, Kirby J, Pioro EP, Pamphlett R, Broach J, Gerhard G, Dunckley TL, Brady CB, Kowall NW, Troncoso JC, Le Ber I, Mouzat K, Lumbroso S, Heiman-Patterson TD, Kamel F, Van Den Bosch L, Baloh RH, Strom TM, Meitinger T, Shatunov A, Van Eijk KR, de Carvalho M, Kooyman M, Middelkoop B, Moisse M, McLaughlin RL, Van Es MA, Weber M, Boylan KB, Van Blitterswijk M, Rademakers R, Morrison KE, Basak AN, Mora JS, Drory VE, Shaw PJ, Turner MR, Talbot K, Hardiman O, Williams KL, Fifita JA, Nicholson GA, Blair IP, Rouleau GA, Esteban-Pérez J, García-Redondo A, Al-Chalabi A; Project MinE ALS Sequencing Consortium, Rogaeva E, Zinman L, Ostrow LW, Maragakis NJ, Rothstein JD, Simmons Z, Cooper-Knock J, Brice A, Goutman SA, Feldman EL, Gibson SB, Taroni F, Ratti A, Gellera C, Van Damme P, Robberecht W, Fratta P, Sabatelli M, Lunetta C, Ludolph AC, Andersen PM, Weishaupt JH, Camu W, Trojanowski JQ, Van Deerlin VM, Brown RH Jr, van den Berg LH, Veldink JH, Harms MB, Glass JD, Stone DJ, Tienari P, Silani V, Chiò A, Shaw CE, Traynor BJ, Landers JE.

Neuron. 2018 Mar 21;97(6):1268-1283.e6. doi: 10.1016/j.neuron.2018.02.027.

40.

Respiratory measures in amyotrophic lateral sclerosis.

Lechtzin N, Cudkowicz ME, de Carvalho M, Genge A, Hardiman O, Mitsumoto H, Mora JS, Shefner J, Van den Berg LH, Andrews JA.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):321-330. doi: 10.1080/21678421.2018.1452945. Epub 2018 Mar 23. Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):478.

PMID:
29566571
41.

Connectivity-based characterisation of subcortical grey matter pathology in frontotemporal dementia and ALS: a multimodal neuroimaging study.

Bede P, Omer T, Finegan E, Chipika RH, Iyer PM, Doherty MA, Vajda A, Pender N, McLaughlin RL, Hutchinson S, Hardiman O.

Brain Imaging Behav. 2018 Dec;12(6):1696-1707. doi: 10.1007/s11682-018-9837-9.

PMID:
29423814
42.

VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics.

Andrews JA, Cudkowicz ME, Hardiman O, Meng L, Bian A, Lee J, Wolff AA, Malik FI, Shefner JM.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):259-266. doi: 10.1080/21678421.2018.1426770. Epub 2018 Feb 6. Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):321.

PMID:
29402141
43.

Longitudinal predictors of caregiver burden in amyotrophic lateral sclerosis: a population-based cohort of patient-caregiver dyads.

Burke T, Hardiman O, Pinto-Grau M, Lonergan K, Heverin M, Tobin K, Staines A, Galvin M, Pender N.

J Neurol. 2018 Apr;265(4):793-808. doi: 10.1007/s00415-018-8770-6. Epub 2018 Feb 2.

PMID:
29396678
44.

Needs of informal caregivers across the caregiving course in amyotrophic lateral sclerosis: a qualitative analysis.

Galvin M, Carney S, Corr B, Mays I, Pender N, Hardiman O.

BMJ Open. 2018 Jan 27;8(1):e018721. doi: 10.1136/bmjopen-2017-018721.

45.

Insular Celtic population structure and genomic footprints of migration.

Byrne RP, Martiniano R, Cassidy LM, Carrigan M, Hellenthal G, Hardiman O, Bradley DG, McLaughlin RL.

PLoS Genet. 2018 Jan 25;14(1):e1007152. doi: 10.1371/journal.pgen.1007152. eCollection 2018 Jan.

46.

Reconsidering the causality of TIA1 mutations in ALS.

van der Spek RA, van Rheenen W, Pulit SL, Kenna KP, Ticozzi N, Kooyman M, Mclaughlin RL, Moisse M, van Eijk KR, van Vugt JJFA, Iacoangeli A, Andersen P, Nazli Basak A, Blair I, de Carvalho M, Chio A, Corcia P, Couratier P, Drory VE, Glass JD, Hardiman O, Mora JS, Morrison KE, Mitne-Neto M, Robberecht W, Shaw PJ, Panadés MP, van Damme P, Silani V, Gotkine M, Weber M, van Es MA, Landers JE, Al-Chalabi A, van den Berg LH, Veldink JH; PROJECT MINE ALS SEQUENCING CONSORTIUM.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb;19(1-2):1-3. doi: 10.1080/21678421.2017.1413118. Epub 2017 Dec 13. No abstract available. Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb;19(1-2):161.

47.

Longitudinal structural changes in ALS: a three time-point imaging study of white and gray matter degeneration.

Bede P, Hardiman O.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):232-241. doi: 10.1080/21678421.2017.1407795. Epub 2017 Dec 7.

PMID:
29214883
48.

Measuring reliable change in cognition using the Edinburgh Cognitive and Behavioural ALS Screen (ECAS).

Crockford C, Newton J, Lonergan K, Madden C, Mays I, O'Sullivan M, Costello E, Pinto-Grau M, Vajda A, Heverin M, Pender N, Al-Chalabi A, Hardiman O, Abrahams S.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb;19(1-2):65-73. doi: 10.1080/21678421.2017.1407794. Epub 2017 Dec 7.

49.

ECAS A-B-C: alternate forms of the Edinburgh Cognitive and Behavioural ALS Screen.

Crockford CJ, Kleynhans M, Wilton E, Radakovic R, Newton J, Niven EH, Al-Chalabi A, Hardiman O, Bak TH, Abrahams S.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb;19(1-2):57-64. doi: 10.1080/21678421.2017.1407793. Epub 2017 Dec 5.

PMID:
29205065
50.

Characteristic Increases in EEG Connectivity Correlate With Changes of Structural MRI in Amyotrophic Lateral Sclerosis.

Nasseroleslami B, Dukic S, Broderick M, Mohr K, Schuster C, Gavin B, McLaughlin R, Heverin M, Vajda A, Iyer PM, Pender N, Bede P, Lalor EC, Hardiman O.

Cereb Cortex. 2019 Jan 1;29(1):27-41. doi: 10.1093/cercor/bhx301.

PMID:
29136131

Supplemental Content

Loading ...
Support Center